Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.53 +0.09 (+0.25%)
Streaming Delayed Price Updated: 11:49 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
27 28 Next >
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4... 
Via Benzinga
Why Atea Pharmaceuticals Stock Is Sinking Today
Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy. 
Via The Motley Fool
Exposures COVID-19
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month... 
Via Benzinga
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Atea Pharma Stock Collapses As Roche Pulls The Plug On Pfizer-Rivaling Covid Pill
Roche and Atea's partnership will end in February. 
Via Investor's Business Daily
Exposures Product Safety
Tuesday Market Overview
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and... 
Via Benzinga
Exposures COVID-19
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
Johnson & Johnson will split its consumer health unit into a publicly traded company. 
Via Investor's Business Daily
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Veteran's Day
Stock markets took a tumble today across the board, but not as far down as at the opening. 
Via Talk Markets
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc... 
Via Benzinga
Exposures COVID-19
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... 
Via Benzinga
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/... 
Via Benzinga
These OTCQX & OTCQB Securities Had the Most Trading Activity in October
Photo by Burak Kebapci from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
The Old Lady Of Threadneedle Street
US markets are up on better jobs growth reported for October today. 
Via Talk Markets
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,... 
Via Benzinga
Exposures COVID-19
Thursday Market Overview
If you are an IBM shareholder you now own something new Kyndryl. 
Via Talk Markets
7 European Stocks to Buy to Diversify Your Portfolio
While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks. 
Via InvestorPlace
Novartis To Offload Its Stake Back To Roche For $20.7B
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting... 
Via Benzinga
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in... 
Via Benzinga
Cyber Currency
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
Default Avoided
The Chinese real estate firm Evergrande managed to pay the interest it owes to foreign bondholders. 
Via Talk Markets
Why Atea Pharmaceuticals Stock Got Crushed This Week
A mid-stage trial miss caused investors to hit the exits this week. 
Via The Motley Fool
Exposures COVID-19
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.